JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat 
Judge Delays SEC Settlement With Elon Musk Over Twitter Stock Disclosure Case 
Morgan Stanley Bets on Optical Component Stocks in Greater China Tech Sector 
Armani Group Eyes Strategic Stake Sale to Luxury Giants 
Coinbase Q1 2026 Earnings Miss Sends COIN Stock Lower Amid Crypto Market Slump 
CoreWeave Q1 2026 Revenue Surges as AI Infrastructure Demand Grows 
Trump Invites Top CEOs Including Nvidia, Apple, Boeing to China Summit With Xi Jinping 
Sony Forecasts Lower 2027 Profit Despite Strong Music and Sensor Growth 
Trump Signals Possible U.S.-Iran Peace Deal as Markets Rally on Hopes of War Ending 
Asian Currencies Slip as US Dollar Gains on Rising Iran Tensions and Awaited Jobs Data 
Japan Tech Stocks Surge as AI Optimism Lifts SoftBank, Chipmakers 
Gold Prices Rise as Weaker Dollar and U.S.-Iran Peace Hopes Boost Demand 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
Lula and Trump Talks Signal New Phase in Brazil-US Relations 
Dollar Struggles to Rally Despite Strong US Data as Fed Hike Expectations Remain Limited 
Pfizer inc., an American pharmaceutical and biotechnology firm headquartered in Manhattan, New York City, has agreed to buy Global Blood Therapeutics biotech company for $5.4 billion. The drugmaker will be paying $68.50 a share for the acquisition.
According to Reuters, Pfizer will purchase the blood disorder medicine producer as it would like to bolster its drug lineup to counter or fight a possible slowdown in the demand for COVID medicines and other products since the cases are starting to fall.
Pfizer was one of the drugmakers that earned the most at the height of the COVID-19 pandemic since it supplied the vaccines around the world. With most people worldwide now fully vaccinated, the company is now looking for acquisitions that will bring in profits annually
Pfizer confirmed on Monday, Aug. 8, that it will be paying $68.50 per share to buy Global Blood Therapeutics. This amount is equivalent to a premium of around 7.3% to the stock's closing price last Friday.
Following the announcement of the deal with Pfizer, the shares of Global Blood reportedly soared by 4.5%. The company is known for its blood disorder drug called Oxbryta, which was first approved in 2019.
It is used for the treatment of sickle cell disease in patients who are 12 years old or older. In December 2021, it was also approved for the treatment of younger patients who are suffering from the said disease.
“Sickle cell disease is the most common inherited blood disorder, and it disproportionately affects people of African descent. We are excited to welcome GBT colleagues into Pfizer and to work together to transform the lives of patients, as we have long sought to address the needs of this underserved community,” Pfizer’s chairman and chief executive officer, Albert Bourla, said in a press release.
He added, “The deep market knowledge and scientific and clinical capabilities we have built over three decades in rare hematology will enable us to accelerate innovation for the sickle cell disease community and bring these treatments to patients as quickly as possible.”
